Clinical analysis of TKIs combined with SBRT in the treatment of renal cell carcinoma with bone metastasis
10.3760/cma.j.cn112330-20200506-00358
- VernacularTitle:靶向药物联合立体定向放疗治疗肾癌骨转移的临床疗效分析
- Author:
Pei DONG
1
;
Yang LIU
;
Wensu WEI
;
Hui HAN
;
Jianhua WU
;
Zhiling ZHANG
;
Shengjie GUO
;
Maosheng LIN
;
Xiaobo JIANG
;
Jianlan FANG
;
Fangjian ZHOU
;
Liru HE
Author Information
1. 中山大学肿瘤防治中心 华南肿瘤学国家重点实验室 肿瘤医学协同创新中心泌尿外科，广州 510060
- From:
Chinese Journal of Urology
2020;41(6):434-438
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of Tyrosine Kinase Inhibitors (TKIs) combined with stereotactic body radiation therapy(SBRT) in the treatment of renal cell carcinoma (RCC) patients with bone metastasis.Methods:The clinical data of 80 RCC patients with bone metastasis in Sun Yat-sen University Cancer Center from April 2010 to April 2020 were analyzed retrospectively. Among them, 64 patients were medium or high risk according to the International Metastatic Renal Cell Carcinoma Database Consortium(IMDC) score. Twenty-four patients received TKI therapy alone(Group A), and the other 56 cases received TKIs combined with SBRT to bone metastastic lesions (Group B).Results:The median follow-up period was 20.7 months (4.8-115.6 months), 70 patients received second or third-line targeted drug therapy, and 4 patients in group A and 15 patients in group B received TKI plus immunotherapy. Fifty-four patients had symptoms of bone pain before radiotherapy, 46 patients were satisfied with the analgesic effect after SBRT treatment. Twelve patients got complete response (CR) after bone lesions, and 32 patients achieved partial response (PR). Forty patients died of disease progression during follow-up. The median OS was: 20.7 months vs not reached(Group A vs. Group B), and the 2-y OS and 5-y OS were 50% vs. 62%, and 19% vs. 56%, respectively ( P=0.006). There were only 2 patients (3.6%) had grade 3 SBRT related adverse events. Conclusions:SBRT combined with TKIs improved the quality of life and prolonged the overall survival of RCC patients with bone metastasis.
